Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema
On October 28, 2025, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase 1b/2a LOTUS-2 clinical trial of novel multivalent fusion antibody (EB-105) for diabetic
read more
Dr. Ashkan Abbey Presented at the American Academy of Ophthalmology Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented, taught and served as a panelist at AAO 2025, the American Academy of Ophthalmology’s annual meeting held in Orlando, Florida, October 18-20, 2025. Highlights of
read more
Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials
At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical
read more
Texas Retina’s Melissa Alva Recognized as a Top Study Coordinator in Clinical Research for 2024
InFocus, an international provider of ophthalmology clinical research and development services, recently named Texas Retina Senior Clinical Research Coordinator Melissa Alva as a “Top Study Coordinator in Retina Clinical Research for 2024,”
read more
New Clinical Trials Available at Texas Retina
At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical
read more
Celebrating Sally Arceneaux’s 31+ Years of Service to Texas Retina
We continue to recognize Texas Retina team members who have served our practice for 20 years or more. Today, we are honoring Sally Arceneaux, who joined Texas Retina in 1992, and currently
read more
Texas Retina Recognizes Laurie Griffis for 35 Years of Service
Since Texas Retina was founded more than 50 years ago, our physicians and leadership have fostered a family environment. As a result, we are fortunate to have numerous team members who have
read more
FDA Approves First Treatment for Geographic Atrophy
On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved intravitreal pegcetacoplan (brand name Syfovre), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Texas Retina
read more
Dr. Abbey’s Research Featured in New Retina Podcast
The medical journal Retina recently released a podcast featuring research by Texas Retina Associates’ Ashkan M. Abbey, MD, on clinical outcomes and surgical technique in transconjunctival sutureless intrascleral fixation of intraocular lenses
read more
Meet Our Plano Clinical Research Coordinators
Tara Keesling and Veronica Bennett are the clinical research coordinators for our Plano office. In addition to enrolling patients in clinical trials for a number of retina conditions like diabetic retinopathy, age-related
read more